Advertisement

Cancer drug key to $21bln pharma deal

AbbVie is to buy Pharmacyclics Inc for about $21 billion. As Hayley Platt reports it continues a growing M&A trend in the sector and will give the drugmaker access to what is expected to be one of the world's top-selling cancer drugs.